Corticobasal syndrome (CBS) is an asymmetric higher cortical dysfunction manifested as parkinsonism, dystonia, and myoclonus. [1] [2] [3] The underlying neuropathology for the CBS phenotype includes corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Alzheimer disease (AD), frontotemporal lobar degeneration, Parkinson disease, and Creutzfeldt-Jakob disease. The frequency of underlying pathology in CBS varies and approximately half of the CBS cases present with CBD (CBS-CBD). Cortical variant PSP (CBS-PSP) and AD (CBS-AD) are each associated with about 20% of CBS cases. 3, 4 The intracellular fibrillary tangles observed in CBD and PSP are composed of 4-repeat tau, whereas both 3-and 4-repeat tau isoforms accumulate in AD.
The radiotracers used to image tau neurofibrillary tangle deposition in the living typical AD brain are 18 F-FDDNP, 5 18 F-AV1451 (T807), 6 11 C-PBB3, 7 and a series of 18 F-THK compounds, such as 18 F-THK523, 8 18 F-THK5105, 9 18 F-THK5117, 10 and 18 F-THK5351. 11 We do not yet know whether these radiotracers detect tau deposits in vivo in patients with CBS. 18 F-FDDNP accumulated in the subthalamic area, midbrain region, and cerebellar white matter of a patient with classical PSP, but not in patients with CBS-PSP. 12 An 11 C-PBB3 PET imaging study also indicated that tau accumulated in the neocortex and in subcortical structures, such as the basal ganglia, thalamus, and midbrain, in a patient with CBS, 7 although this observation has not been confirmed in a case-control study. 18 F-THK5351 is a novel radiotracer with a high binding affinity and selectivity for tau protein deposits. 11 We evaluated whether 18 F-THK5351 PET can selectively bind to tau pathology in living patients with CBS.
METHODS Autoradiography. THK5351 was synthesized from its tosylate precursor, (S)-2-(2-methylaminopyrid-5-yl)-6-[[2-(tetrahydro-2H-pyran-2-yloxy)-3-tosyloxy]propoxy] quinoline (THK5352), as described previously. 11,13 3 H-THK5351 (specific activity, 2.96 TBq/mmol; radiochemical purity, 98.9%) was custom-labeled by Sekisui Medical Inc. (Tokyo, Japan).
11
Autoradiography in middle frontal gyrus postmortem brain sections from a 65-year-old woman with CBD was conducted using 3 H-THK5351 and tau (AT8) immunostaining, as described previously. 11 We estimated the concentration relationship between the 3 H-THK5351 autoradiography and tau (AT8) immunostaining in 5 regions of interest each of gray matter and white matter using the ImageQuant TL software (GE Healthcare, Piscataway, NJ).
Participants. Five patients with CBS (one male and 4 female, age 69.2 6 7.0 years, age range 64-81 years, Mini-Mental State Examination [MMSE] score 20.0 6 7.9), 8 age-matched normal controls (4 male and 4 female, age 71.1 6 6.9 years, age range 61-81 years, MMSE score 28.6 6 1.6), and 8 age-matched patients with amnestic AD (5 male and 3 female, age 76.6 6 8.4 years, age range 64-88 years, MMSE score 18.1 6 4.7) underwent 18 F-THK5351 PET scans. Probable CBS was diagnosed based on the modified Cambridge criteria.
14 All patients were right-handed. Three of the 5 patients had rightside dominant symptoms and 2 of them were left-side dominant. The Montreal Cognitive Assessment, Addenbrooke's Cognitive Examination-Revised, and Frontal Assessment Battery were used to assess the cognitive performance of the participants. Motor functions were assessed using the Unified Parkinson's Disease Rating Scale motor score and the PSP Rating Scale. We also examined the results of the Odor Stick Identification Test for Japanese, a CSF study, and 123 I-metaiodobenzylguanidine (MIBG) and dopamine transporter (DAT) scans. The normal control group comprised volunteers with no cognitive or motor function impairments, who did not have any observable cerebrovascular lesions as indicated by MRI scans. Probable AD was diagnosed based on the criteria of the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease Related Disorders Association. Some of the data from normal controls and patients with AD were presented in our previous article.
Standard protocol approvals, registrations, and patient consents. The study protocol was approved by the Ethics Committee of the Tohoku University Hospital (approval number: 2014-2-159) and was registered to the UMIN Clinical Trial Registry (registration number: UMIN000013929). Written informed consent was obtained from each patient or his or her guardians after they were given a complete description of the study.
Image acquisition.
18 F-THK5351 and 11 C-Pittsburgh compound B (PiB) was prepared at the Cyclotron and Radioisotope Center of Tohoku University using a semiautomated system developed in-house. Injectable solutions of 18 F-THK5351 and 11 C-PiB were obtained at a radiochemical purity of .95% and a specific activity of 357 6 270 and 240 6 48 GBq/mmol. PET imaging was performed using an Eminence STARGATE scanner (Shimadzu, Kyoto, Japan). After injecting 185 MBq of 18 F-THK5351 or 296 MBq of 11 C-PiB, PET images were obtained for 20 minutes (4 scans 3 300 seconds) from 40 to 60 minutes or from 50 to 70 minutes postinjection and were used for further analysis. A 3D volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of thin axial sections using a spoiled gradient recall sequence Erlangen, Germany). DAT images were acquired 3 hours after an IV injection of 167 MBq of 123 I-ioflupane (Nihon Medi-Physics Co, Ltd., Tokyo, Japan) using a Symbia-E (Siemens).
Image analysis. Standardized uptake value (SUV) images of 18 F-THK5351 and 11 C-PiB were obtained by normalizing the tissue radioactivity concentration to the injected dose and body weight. The PNEURO module in PMOD software (version 3.6; PMOD Technologies, Zurich, Switzerland) was used to place and evaluate the volumes of interest (VOIs) using an automatic VOI method. The PET images were matched rigidly to the T1-weighted MRIs acquired from each participant. The MRIs were spatially normalized to the Montreal Neurological Institute T1 MRI template. VOIs were automatically outlined on the normalized MRI based on the maximum probability atlas constructed by Hammers et al., which is used in the Table 1 Demographic characteristics of patients with corticobasal syndrome (CBS) PMOD software. VOIs were defined in the following regions: bilateral precentral, postcentral, superior frontal, superior parietal, and posterior cingulate gyri, globus pallidus, putamen, caudate nucleus, substantia nigra, middle and inferior temporal gyrus, hippocampus, amygdala, and cerebellar gray matter. The cerebellar gray matter was used as a reference region. The regional SUV to cerebellar cortex SUV ratio (SUVR) was used as an index of tracer retention. Neocortical b-amyloid burden was expressed as the average SUVR for the following cortical volumes of interest: superior frontal, superior parietal, middle and inferior temporal, and posterior cingulate gyri for 11 C-PiB. As in previous studies, an 11 C-PiB SUVR threshold of 1.5 was used to categorize high and low b-amyloid burden.
9,15,16 Z score maps were created using the mean and SD images from 8 normal controls. Voxel-based group comparisons between normal controls and patients with CBS or with AD and between patients with CBS and with AD were performed using statistical parametric mapping software Cardiac 123 l-MIBG accumulation was evaluated using the heart to mediastinum (H/M) ratio. Striatal 123 I-Ioflupane accumulation was evaluated by specific binding ratio (SBR) calculation using an occipital lobe as a background region.
Statistical analysis. We used a repeated-measures analysis of variance followed by Holm-Sidak multiple comparisons test to compare regional SUVR values of 18 F-THK5351 and 11 C-PiB in normal controls vs patients with CBS. Effect size coefficients (Cohen d) were calculated to evaluate group differences in the PET measurements. The analyses were performed using GraphPad Prism6 software (GraphPad, San Diego, CA). Data were expressed as mean 6 SD. 
org).
Clinical features of patients with CBS. Table 1 summarizes the clinical features of the patients with CBS. Age was not significantly different among the 3 groups. As expected, we observed significant differences between the CBS and normal control groups in their MMSE scores. CBS cases showed no remarkable decrease in the levels of Ab1-42 in CSF. In one study, 17 scores below 1 using the formula Ab1-42/ (152 1 8.25 3 p-tau) in CSF showed AD at a high rate in 16 out of 17 cases, the diagnoses of which were confirmed by autopsy. All CBS cases showed a high score of more than 1 (table 1). DAT scans in 4 CBS patients, but not case 4, showed a "dot" appearance in the basal ganglia predominantly contralateral to the affected symptoms (data not shown) and SBR were less than 4.5 in 4 CBS patients except for case 4, which is not typically observed in AD. Both early and delayed H/M ratios of all CBS patients were greater than 2.2.
Clinical PET studies in healthy elderly controls and patients with CBS.
18
F-THK5351 PET images and Z score maps in a normal control (61-year-old female, MMSE score 30) and 5 patients with CBS are shown in figure 2, A and B. We observed 18 F-THK5351 retention in the precentral and postcentral gyri, and basal ganglia in patients with CBS ( figure 2A) . In all patients with CBS, a higher uptake of 18 F-THK5351 was seen in the contralateral precentral, postcentral, superior frontal, and superior parietal gyri of the symptom-predominant side (figure 2, A and B, and table 2). 18 F-THK5351 SUVR values for the bilateral precentral, postcentral, superior frontal, and superior parietal gyri and globus pallidus and left posterior cingulate gyrus were significantly greater in patients with CBS than in normal controls (figure 2C and tables 3 and e-1). On the other hand, no significant differences between the 2 groups were found in the bilateral caudate nuclei, substantia nigra, middle inferior temporal gyri, hippocampus, and amygdala or right posterior cingulate gyrus (table 3) . We performed voxel-by-voxel comparisons of 18 F-THK5351 PET images in CBS, AD, and normal groups. We observed higher 18 F-THK5351 retention in the precentral and postcentral gyri and premotor area in the CBS group than that in the normal control group, while the AD group showed higher 18 F-THK5351 retention in the medial and inferior temporal gyri and occipital lobes than the normal control group (uncorrected p , 0.001, figure e-2). Compared to the AD group, the CBS group showed higher 18 F-THK5351 retention in the bilateral precentral gyrus and right globus pallidus (uncorrected p , 0.001, figure e-2) and lower F-THK5351 retention in the parahippocampal gyrus and inferior temporal cortex (data not shown). The b-amyloid burden in the current CBS cases was additionally examined using PiB-PET (table 1) . Four out of 5 CBS cases showed no remarkable b-amyloid burden. One CBS case (case 2) showed high b-amyloid burden; however, no remarkable atrophy was observed in the hippocampus of this patient. There were no significant differences in 11 C-PiB retention between CBS and normal control groups (tables e-2 and e-3).
DISCUSSION 3 H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD ( figure 1 ). Higher accumulation of 18 F-THK5351 was seen in the precentral and postcentral gyri, and globus pallidus in patients with CBS than in normal controls ( figure 2 and table 3) . The spatial patterns of 18 F-THK5351 binding were compatible with tau deposit distributions observed in brain autopsies of patients with CBS-CBD, 18 CBS-PSP, 19 and CBS-AD. 20 These results strongly suggest that 18 F-THK5351 PET is able to visualize tau deposits in patients with CBS. In the future, image-to-autopsy studies are necessary to validate the binding ability of this tracer to tau lesions in CBD.
We observed that 4 out of 5 CBS cases showed negative amyloid PET scans, indicating that 18 F-THK5351 retention in these 4 CBS cases is not likely to reflect concomitant AD pathology. The spatial distribution of 18 F-THK5351 uptake differed greatly between CBS and AD cases. No remarkable uptake of 18 F-THK5351 was observed in the medial and inferior temporal lobes of patients with CBS (figures 2 and e-2). The findings of CSF analysis also supported that these CBS cases do not have AD pathology. One CBS case (case 2) showed high b-amyloid burden, suggesting that this case is CBS-CBD with incidental or preclinical b-amyloid burden, because b-amyloid burden is observed in 20%-30% of normal elderly individuals. 16, 21, 22 Another possibility is that this case has AD-related tau deposits in the neocortex, which is comparable to hippocampal sparing AD. 23, 24 Our patients with CBS are more likely to be CBS-CBD than CBS-PSP, as their p-tau to total tau ratio in CSF was 0.18 or lower. 25 18 F-THK5351 PET may help to differentiate between CBS-CBD and CBS-PSP. Patients with CBS-CBD show a greater tau burden in the primary motor and somatosensory cortices and in the putamen than those with CBS-PSP. 18 In a future study, the spatial pattern of 18 F-THK5351 binding should be compared between CBS-CBD and CBS-PSP cases.
One limitation of this study was that we have not performed postmortem examination in the current CBS cases and could examine only one CBD brain sample from a different patient, owing to the limited availability of well-characterized autopsy samples. Autoradiography with multiple and scanned cases will improve the reliability of 18 F-THK5351 PET imaging. Another limitation was the relatively small sample size. We therefore could not examine the association between 18 F-THK5351 retention and clinical severity in CBS. Nevertheless, a higher accumulation of 18 F-THK5351 was seen in the cortical regions and globus pallidus of the side contralateral to the symptom-predominant side (figure 2, A and B, and table 2), suggesting that the spatial distribution of the tracer signal may explain the clinical symptoms in CBS. 18 F-THK5351 retention may not increase in alignment in proportion to the severity of the illness and may change in the same manner as an inverted parabola in response to neuronal cell loss. 18 F-THK5351 PET demonstrated high tracer signals in sites susceptible to tau deposition in patients with CBS. 18 F-THK5351 should be considered as a clinical tool in the assessment of tau burden in CBS. Future clinical studies should clarify whether the radiotracer is a suitable biomarker for the early diagnosis and monitoring of disease progression in CBS. 18 F-THK5351 may also be a potential tool for monitoring the effects of anti-tau-specific therapeutics in patients with CBS.
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